Latteno Announces New Corporate IVR System and Upgraded IR Department

Full-time on-site IR personnel have been retained to handle all incoming and outgoing investor email and phone inquiries. The revitalized IR upgrade has been necessitated by anticipated present and near-term future growth prospects, and is in line with the Company’s mission to provide all investors timely and accurate information regarding relating to its aggressive growth journey.

The new telephone IVR system can be accessed through the Company’s new corporate number (844) 332-7101, which will provide each caller will menu prompts to properly direct their calls, whether to corporate headquarters, Investor Relation or even to Rx Harvest Collective to inquire about MMJ delivery service.

Additionally, and concurrently with the IR and IVR upgrade, the Company’s in-house IT, Business Development and Operations departments, have commenced the overall re-design and development of new branding and contents for Latteno.com site. The new design and website content will reflect our soon to be announced new directions and initiatives.

Earlier this month, the Company announced the Partnership with a Pre-ICO Prop D medical dispensary operating out of Los Angeles CA, which added 4 New Marijuana Strains to its offering, and the signing of a comprehensive Joint Venture Agreement with a Denver based third party grower to begin production on a 35 acre farm in Peyton CO. Initial projections indicated that Production yields could reach as much a $200,000 monthly.

The Company has also made real progress on numerous fronts both in California, Nevada and, their new home, Colorado. Specific initiatives include the MMJ Delivery Service, MMJ Grower Warehouse facilities, MMJ Dispensaries and MMJ Evaluation Offices. Each of these initiatives has been developed to provide complementary sustainable revenue streams to each market it opens. The Partnership with Pre-ICO Greenlight Discount Pharmacy and the addition to Premier Marijuana Strains through its distribution Channels represent positive steps forward in the Company’s MMJ Strategy.

Additionally, the Company’s recently announced diversification into the lucrative Sex Enhancement – Erectile Dysfunction Treatment Industry with the introduction of the its Proprietary LT-512 100% Natural Sex Enhancement that increases sexual arousal in both men and women, and is a safe and effective treatment for Erectile Dysfunction that does not required a doctor’s prescription.

The Company’s entry into Erectile Dysfunction and Sexual Enhancement Treatments across a number of its operating divisions represents substantial additional revenue streams in a new major market, in addition to those currently being developed in the Medical Marijuana Market (MMJ) and the seafood distribution industry.